Momenta Pharmaceuticals, Inc. (MNTA): Price and Financial Metrics


Momenta Pharmaceuticals, Inc. (MNTA)

Today's Latest Price: $32.40 USD

0.30 (-0.92%)

Updated Aug 6 6:55pm

Add MNTA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MNTA Stock Summary

  • The ratio of debt to operating expenses for Momenta Pharmaceuticals Inc is higher than it is for about just 0.34% of US stocks.
  • MNTA's price/sales ratio is 132.36; that's higher than the P/S ratio of 97.66% of US stocks.
  • As for revenue growth, note that MNTA's revenue has grown -61.73% over the past 12 months; that beats the revenue growth of merely 2.8% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Momenta Pharmaceuticals Inc, a group of peers worth examining would be EYES, VUZI, ATNX, ZNGA, and DAIO.
  • Visit MNTA's SEC page to see the company's official filings. To visit the company's web site, go to www.momentapharma.com.
MNTA Daily Price Range
MNTA 52-Week Price Range

MNTA Stock Price Chart Technical Analysis Charts


MNTA Price/Volume Stats

Current price $32.40 52-week high $39.88
Prev. close $32.70 52-week low $11.29
Day low $31.94 Volume 484,400
Day high $33.17 Avg. volume 1,188,709
50-day MA $33.25 Dividend yield N/A
200-day MA $27.00 Market Cap 3.81B

Momenta Pharmaceuticals, Inc. (MNTA) Company Bio


Momenta Pharmaceuticals is specializing in the detailed structural analysis of complex drugs and applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications. The company was founded in 2001 and is based in Cambridge, Massachusetts.





MNTA Latest News Stream


Event/Time News Detail
Loading, please wait...

MNTA Latest Social Stream


Loading social stream, please wait...

View Full MNTA Social Stream

Latest MNTA News From Around the Web

Below are the latest news stories about Momenta Pharmaceuticals Inc that investors may wish to consider to help them evaluate MNTA as an investment opportunity.

Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN

CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the prevention of hemolytic disease of the fetus and newborn (HDFN). Additionally, FDA granted nipocalimab orphan drug designation in HDFN. HDFN is a serious blood disorder in a fetus or newborn that occurs when red blood cell incompatibility exists between the blood types of a mother and fetus in utero. “In HDFN, a mismatch in parent’s blood group antigens causes the mother’s immune system to recognize the fetus’ red blood cells as foreign.  This results in the development of pathogenic antibodies that transfer across the placenta ...

Yahoo | July 28, 2020

Will Momenta Pharmaceuticals (NASDAQ:MNTA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | July 24, 2020

Did Hedge Funds Make The Right Call On Momenta Pharmaceuticals, Inc. (MNTA) ?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 13, 2020

Top Ranked Momentum Stocks to Buy for July 6th

Top Ranked Momentum Stocks to Buy for July 6th

Yahoo | July 6, 2020

The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals

The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals

Yahoo | June 29, 2020

Read More 'MNTA' Stories Here

MNTA Price Returns

1-mo -6.09%
3-mo -1.10%
6-mo 1.66%
1-year 177.16%
3-year 99.38%
5-year 46.74%
YTD 64.22%
2019 78.71%
2018 -20.86%
2017 -7.31%
2016 1.42%
2015 23.26%

Continue Researching MNTA

Want to see what other sources are saying about Momenta Pharmaceuticals Inc's financials and stock price? Try the links below:

Momenta Pharmaceuticals Inc (MNTA) Stock Price | Nasdaq
Momenta Pharmaceuticals Inc (MNTA) Stock Quote, History and News - Yahoo Finance
Momenta Pharmaceuticals Inc (MNTA) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.814 seconds.